Inhibition of Bromodomain and Extraterminal Domain Reduces Growth and Invasive Characteristics of Chemoresistant Ovarian Carcinoma Cells Publisher Pubmed



Momeny M¹ ; Eyvani H² ; Barghi F² ; Ghaffari SH² ; Javadikooshesh S⁶ ; Jamadi RH² ; Esmaeili F² ; Alishahi Z² ; Zaghal A² ; Bashash D⁷ ; Samani FS⁸ ; Ghaffari P² ; Dehpour AR^{4, 5} ; Tavangar SM³ Show All Authors Show Affiliations
Source: Anti-Cancer Drugs Published:2018

Abstract

Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy worldwide. Development of chemoresistance and peritoneal dissemination are the major reasons for low survival rate in the patients. The bromodomain and extraterminal domain (BET) proteins are known as epigenetic 'readers,' and their inhibitors are novel epigenetic strategies for cancer treatment. Accumulating body of evidence indicates that epigenetic modifications have critical roles in development of EOC, and overexpression of the BET family is a key step in the induction of important oncogenes. Here, we examined the mechanistic activity of I-BET151, a pan-inhibitor of the BET family, in therapy-resistant EOC cells. Our findings showed that I-BET151 diminished cell growth, clonogenic potential, and induced apoptosis. I-BET151 inhibited cell proliferation through down-modulation of FOXM1 and its targets aurora kinase B and cyclin B1. I-BET151 attenuated migration and invasion of the EOC cells by down-regulation of epithelial-mesenchymal transition markers fibronectin, ZEB2, and N-cadherin. I-BET151 synergistically enhanced cisplatin chemosensitivity by down-regulation of survivin and Bcl-2. Our data provide insights into the mechanistic activity of I-BET151 and suggest that BET inhibition has potential as a therapeutic strategy in therapy-resistant EOC. Further in vivo investigations on the therapeutic potential of I-BET151 in EOC are warranted. © 2018 Wolters Kluwer Health, Inc.